12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SD-809: Phase III started

Auspex began the double-blind, placebo-controlled, North American Phase III First-HD trial evaluating 6, 9 and 12 mg oral SD-809 in 90 HD patients who have not...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >